Cre/lox Studies Identify Resident Macrophages as the Major Source of Circulating Coagulation Factor XIII-A by Beckers, CML et al.
1494
Factor (F)XIII-A is a moderately abundant plasma coagu-lation protein with a half-life of 5 to 10 days1; therefore, 
the cell type that releases FXIII-A into the plasma must be 
reasonably numerous. In mammals, FXIII-A is expressed in 
megakaryocytes, monocytes, osteocytes, chondrocytes, den-
dritic cells, and bone marrow (BM)–derived macrophages, 
which have polarized to the M2 phenotype.2 FXIII-A is 
expressed in resident macrophages in organs, including heart, 
aorta, skin, and placenta,3–5 but not in liver, spleen, and kid-
ney.6 FXIII-A lacks a classical signal peptide,7 and its mecha-
nism of release remains uncharacterized. As a consequence, 
plasma FXIII-A may not be released from every cell type in 
which it is expressed. The outcomes of human BM transplant 
(BMT) studies have variously implicated platelets, macro-
phages, and unidentified extra-hematopoietic cells as possible 
sources of plasma FXIII-A.8–11 Our previous studies suggested 
that the platelet is not the source of plasma FXIII-A because 
in 2 severely thrombocytopenic mouse lines, BCl
x
Plt20/Plt20
 
and Mpl−/−, plasma FXIII-A levels were normal.3 However, a 
possibility that we did not fully address is that thrombocyto-
penia per se might induce upregulation of platelet proteins, 
including FXIII-A, either within the megakaryocyte lineage 
or within a rescuing cell type. Therefore, in the current study, 
we have measured FXIII-A in platelets from the Mpl−/− mouse 
and have investigated the source of plasma FXIII-A by cross-
ing a novel FXIII-A floxed mouse with mice that individually 
express platelet factor (Pf)4-cre, integrin αM (CD11b)-cre, or 
lysozyme 2 (LysM)-cre. CD11b is highly expressed on mono-
cytes, inflammatory macrophages, and osteoclasts and is low 
or absent in certain populations of yolk sac (YS)–derived 
macrophages,12,13 while LysM is expressed on numerous mac-
rophage subpopulations.14 The Pf4-cre was designed to delete 
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in the platelet lineage,15 but a recent reporter mouse study has 
also shown Pf4-cre expression within resident macrophages.16
In this study, we relate the extent of plasma FXIII-A depletion 
to the loss of FXIII-A mRNA levels in our cre/lox crosses and 
deduce that a macrophage population maintains plasma FXIII-A.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Plasma FXIII-A Levels Are Consistent 
With Either a Platelet or a Myeloid Origin 
in cre/lox FXIII-A-Deficient Mice
The presence of the flippase recombinase target or LoxP sites 
within the F13a1 gene of the floxed mouse (Figure I in the 
online-only Data Supplement) slightly decreased plasma FXIII-A 
activity to 85±5% of C57BL/6 wild-type (WT) mice (Figure 1A). 
Consequently, results are presented either relative to WT mice 
(Figure 1A) or, where more appropriate, relative to FXIII-A.Flox 
mice (Figure 1B). Plasma FXIII-A activity was absent in the 
novel FXIII-A−/− mouse, while plasma FXIII-A activity in het-
erozygous mice was 61±3% (P<0.001; Figure 1A), in agreement 
with previously described FXIII-A+/− mice.17 FXIII-A activity 
measurements were corroborated by immunoblotting, with gen-
erally good agreement between methods (Figure 1).
FXIII-A.Flox mice were crossed with mice expressing cre 
recombinase in megakaryocytes and certain macrophage pop-
ulations (Pf4-cre15,16) or exclusively in myeloid cells (LysM-
cre14 and CD11b-cre13). In Pf4-cre.Flox mice, plasma FXIII-A 
activity was reduced to 23±3% (P<0.001; Figure 1B). To deter-
mine whether the residual 23% was explained by suboptimal 
Pf4-cre expression, we bred mice harboring 2 copies of this 
transgene, using quantitative polymerase chain reaction of 
genomic (g)DNA to assess copy number (1 copy normalized to 
1.00±0.038, n=12 and 2 copy to 1.83±0.060, n=6).
Pf4-cre.cre.Flox mice did not show a statistically sig-
nificant further decrease in plasma FXIII-A activity (17±1%, 
P=0.48; Figure 1B), suggesting that incomplete depletion is 
not explained by suboptimal expression of Pf4-cre.
In CD11b-cre.Flox and LysM-cre.Flox mice, plasma 
FXIII-A was reduced to 75±5% (P=0.003; Figure 1B) and 
57±5% (P<0.001; Figure 1B), respectively. The LysM-cre 
knock-in undergoes silencing,18 and possibly on account of 
this, we observed a significant further reduction in plasma 
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Figure 1. Plasma factor (F)XIII-A activity was measured by biotin-pentylamine incorporation (red bars). Activity measurements were con-
firmed by immunoblotting FXIII-A protein normalized to α1-antitrypsin (blue bars). A, Relates FXIII-A activity in wild-type (WT) mice (100%) 
to mice in which FXIII-A expression originates from the WT allele and also to the FXIII-A.Flox mouse. B, Relates FXIII-A activity in FXIII-A.
Flox mice (100%) to crosses between the FXIII-A.Flox and –cre expressing mice. Numbers of separate mouse samples are shown in 
parentheses. Results are displayed as mean±SEM. Pf4-cre.cre and LysM-cre.cre are homozygous for the respective transgenes. CD11b 
indicates integrin αM; Flox, FXIII-Aflox/flox; LysM, lysozyme 2; and Pf4, platelet factor 4.
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FXIII-A (to 30±7%) in 2-copy LysM-cre.cre.Flox mice rela-
tive to LysM-cre.Flox mice (P<0.001; Figure 1B).
The sum of the plasma FXIII-A reductions achieved 
individually with Pf4-cre.Flox (77%) and either CD11b-
cre.Flox (25%) or LysM-cre.cre.Flox (70%), respectively, 
equals or exceeds 100%. In contrast, while dual-express-
ing CD11b-cre.Pf4-cre.Flox mice showed a further reduc-
tion in plasma FXIII-A activity (11±2%; Figure 1B) over 
the Pf4-cre.Flox mice (P<0.001), plasma FXIII-A was 
not completely eliminated. These results suggest that the 
plasma FXIII-A-releasing cell expresses both Pf4 and 
myeloid markers.
Platelet FXIII-A Concentrations in cre/lox 
FXIII-A-Deficient and Thrombocytopenic 
Mpl−/− Mice Discount the Platelet and Support 
a Myeloid Origin for Plasma FXIII-A
Although our previous studies suggested that the plate-
let was not the source of plasma FXIII-A,3 the substantial 
deletion of plasma FXIII-A in Pf4-cre.Flox mice might be 
A
D
C
B
Figure 2. A, Platelet counts in whole blood were determined by flow cytometry. B, Platelets from wild-type (WT; blue dots) and Mpl−/− mice 
(red dots) were stained with fluorescein isothiocyanate (FITC)–labeled and phycoerythrin (PE)-labeled anti-GPIbα antibodies, respectively. 
The plot of forward scatter (FSC-A) vs side scatter (SC-A) shows a similar size distribution in WT and Mpl−/− platelets and is representative 
of 3 independent experiments. C and D, Platelet factor (F)XIII-A activity was measured over the linear range by biotin-pentylamine incorpo-
ration and adjusted for lactate dehydrogenase (LDH) activity (red bars). Activity measurements were confirmed by immunoblotting, normal-
ized to β-actin (blue bars). Numbers of separate mouse samples are shown in parentheses. Results are displayed as mean±SEM relative to 
WT (C) or FXIII-A.Flox (D) as appropriate. CD11b indicates integrin αM; Flox, FXIII-Aflox/flox; LysM, lysozyme 2; and Pf4, platelet factor 4.
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interpreted as indicating that the megakaryocyte–platelet 
lineage makes a significant contribution to plasma FXIII-A. 
To further exclude the platelet lineage as the major source of 
plasma FXIII-A, we demonstrated that Mpl−/− mice have nor-
mal plasma FXIII-A activity (95±4%, P=0.49; Figure 1A), 
despite platelet counts in whole blood being 6.4±5% of WT 
(P<0.0001). In contrast, platelet counts did not differ between 
WT mice and the various cre/lox mice (Figure 2A). We 
established that the size distribution of Mpl−/− platelets was 
equivalent to that of WT (Figure 2B) and that FXIII-A activ-
ity and protein per platelet were normal (92±6%; Figure 2C). 
In addition, because thrombocytopenia has been suggested 
to induce hepatic FXIII-A expression,9 we determined by 
reverse transcriptase polymerase chain reaction that hepatic 
FXIII-A mRNA was undetectable in either the Mpl−/− or WT 
mice (Ct>40). Together, these results both exclude compensa-
tory FXIII-A upregulation in platelets or hepatic cells as a 
mechanism whereby plasma FXIII-A is maintained and fur-
ther discount the platelet as the source of plasma FXIII-A.
In the platelet, FXIII-A activity was abolished in Pf4-cre.
Flox mice (Figure 2D), showing that single-copy Pf4-cre mice 
underwent efficient deletion. Moreover, platelet FXIII-A was 
unaffected in the CD11b-cre.Flox (83±10%), LysM-cre.Flox 
(111±3%), and LysM-cre.cre.Flox (94±10%) mice (Figure 2D), 
A D
FE
C
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Figure 3. A, Genomic F13a1 recombination in the tissues indicated was determined in Pf4-cre.Flox (dark bars) and CD11b-cre.Flox (white 
bars) mice. Results are expressed as mean±SEM (n≥3). B and C, Immunofluorescent staining detects factor (F)XIII-A (red) cells in wild-
type (WT) but not FXIII-A−/− heart sections. Nuclei are shown in blue. B, A proportion of FXIII-A-labeled cells adopt a spindle-shaped mor-
phology characteristic of cardiac macrophages (inset). Scale bar represents 50 μm. C, Some of these FXIII-Apos cells costain for CD163 
(green). Scale bar is 5 μm. D–F, mRNA was isolated from indicated tissues and cDNA subjected to quantitative polymerase chain reaction 
(qPCR) using housekeeping (HK) transcripts ribosomal protein L32 and β-actin. All results are displayed as mean with 95% confidence 
interval (CI). D, FXIII-A mRNA expression was measured in heart (light yellow bars) and aorta (dark yellow bars) in mice of the genotypes 
indicated. Numbers of separate mouse samples are shown in parentheses. E, Endogenous Pf4 transcripts (light pink bars) in WT aorta 
and heart (n=4) were measured by reverse transcriptase (RT)-PCR, and reaction products were resolved on agarose gels (inset). Transcript 
levels were enriched in WT-cultured BM-derived macrophages (BMDM, n=4) at levels similar to endogenous CD11b transcripts (dark pink 
bars), as well as in a FXIII-A-enriched cardiac cell fraction (FEF, n=4). F, FXIII-A mRNA expression was measured in brains (n=3) of young 
mice of the genotypes indicated. CD11b indicates integrin αM; Flox, FXIII-Aflox/flox; LysM, lysozyme 2; and Pf4, platelet factor 4.
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confirming that these myeloid-cre mice exert their effects on 
plasma FXIII-A through the myeloid rather than the megakaryo-
cyte lineage. Together, these results suggest that Pf4-cre depletes 
plasma FXIII-A by acting within myeloid cells, and that these 
cells are the major site from which plasma FXIII-A is released.
FXIII-Apos Cardiac Cells Are Pf4-
Expressing Macrophages
We assayed the extent of F13a1 genomic deletion using 
quantitative polymerase chain reaction of gDNA, with refer-
ence to a standard curve (Figure II in the online-only Data 
Supplement). Genomic F13a1 recombination was essen-
tially as previously described in the organs of CD11b-cre.
Flox mice.13 In Pf4-cre.Flox mice, genomic deletion totaled 
3.5% in heart and 3.4% in aorta and was lower in other organs 
examined (Figure 3A), excluding the possibility that Pf4-cre 
expression was promiscuous in Pf4-cre.Flox mice.
We examined the expression of FXIII-A mRNA in heart and 
aorta, where functional roles of FXIII-A have been described.19,20 
Immunofluorescence studies revealed FXIII-Apos cells in WT, but 
not knockout heart (Figure 3B). Some of these FXIII-Apos cells 
appeared as spindles (inset Figure 3B), in agreement with their 
previous identification as macrophages.21 Moreover, coimmuno-
fluorescence for CD163 and FXIII-A (Figure 3C) and immuno-
histochemistry of consecutive WT heart sections (Figure III in 
the online-only Data Supplement) confirmed that ≈80% of the 
FXIII-Apos cells are CD163pos macrophages (Table 1).
FXIII-A mRNA was abolished in heart and depleted in aorta 
in Pf4cre.Flox mice (Figure 3D). The complete depletion of 
FXIII-A mRNA in the heart is broadly consistent with the extent 
of gDNA recombination (3.5%) and the frequency of FXIII-Apos 
cells (5%; Table 1), provided that Pf4-cre expression is restricted to 
FXIII-Apos cells. Importantly, in LysM-cre.cre.Flox mice, FXIII-A 
mRNA was substantially depleted from these tissues, while it was 
conserved in the Mpl−/− mouse, confirming that FXIII-Apos cells are 
myeloid rather than platelet/megakaryocyte in origin. As expected, 
the proportional deletion of the FXIII-A mRNA reflected the loss 
of FXIII-Apos cells across the various genotypes (Table 1).
Authentic Pf4 transcripts were detected in WT hearts and 
aorta (insert, Figure 3E), as well as in Mpl−/− hearts (data not 
shown). Pf4 transcripts were 40-fold enriched in cultured 
BM-derived macrophages over whole hearts, while the ratio 
of Pf4 mRNA to CD11b mRNA was comparable between 
BM-derived macrophages and whole heart (Figure 3E). This 
is consistent with Pf4 and CD11b mRNA being present at a 
similar concentration within cardiac macrophages, which rep-
resent a minor proportion of the tissue.
Finally, we analyzed cell fractions from collagenase-digested 
hearts obtained with the Miltenyi neonatal cardiac fibroblast 
isolation kit. In a fraction that was ≈8-fold enriched in FXIII-A 
mRNA (FEF) and which represented ≈3% of total heart cell 
mass, Pf4 and CD11b mRNA were, respectively, 20-fold and 
14-fold enriched (Figure 3E). Together, these data indicate that 
the FXIII-Apos cardiac cells are Pf4-expressing macrophages.
Plasma FXIII-A Originates From Cells 
Resembling Aortic Macrophages
In the brain, where because of the blood–brain barrier, macro-
phages derive exclusively from primitive YS hematopoiesis,22,23 
we observed that FXIII-Apos cells are present at similar levels 
Table 1. Cardiac Cross Sections From Mice of the Genotypes Indicated Were Immunofluorescently Labeled for CD163 and FXIII-A
 Total No. of Cells
No. of  
FXIII-Apos Cells
Percent of  
FXIII-Apos Cells
No. of  
CD163pos Cells
No. of Double  
Pos. Cells
Percent of FXIII-
Apos Cells That Are 
CD163pos
C57Bl/6 4424 245 5.54 223 208 84.90
FXIII-A KO 4551 0 0.00 86 0 0.00
Pf4-cre.Flox 4515 7 0.15 124 5 71.43
CD11b-cre.Flox 6012 209 4.40 213 122 58.37
LysM-cre.cre.Flox 5387 37 0.68 92 12 32.43
The values show the total amount of cells counted, as well as those positive for FXIII-A and CD163. The percentage of total FXIII-Apos cells was as expected from the 
FXIII-A mRNA levels shown in Figure 3D. A high proportion of FXIII-Apos cells costained for CD163, suggesting that they are macrophages. CD11b indicates integrin αM; 
Flox, FXIII-Aflox/flox; KO, knockout; LysM, lysozyme 2; and Pf4, platelet factor 4.
Table 2. Comparison of Plasma and Platelet FXIII-A Enzyme Activities With FXIII-A mRNA Levels in Heart and Aorta
Genotype Plasma Activity Platelet Activity Cardiac mRNA Aortic mRNA
Mpl−/− 0.95 0.06* 0.93 1.70
FXIII-A.Flox 0.83 0.87 0.76 0.85
Pf4-cre.Flox 0.19 <0.01 <0.01 0.14
CD11b-cre.Flox 0.62 0.83 0.93 0.60
LysM-cre.cre.Flox 0.30 0.94 0.20 0.41
Values are shown relative to WT mice represented as 1.0. Depletion of cardiac FXIII-A mRNA in the Pf4-cre.Flox mouse greatly exceeds depletion of the plasma pool, 
making cardiac tissue an unlikely source of plasma FXIII-A. Depletion of FXIII-A mRNA in the aorta, however, generally reflects the depletion of plasma FXIII-A. CD11B 
indicates integrin αM; Flox, FXIII-Aflox/flox; FXIII-A, factor XIII-A; LysM, lysozyme 2; and Pf4, platelet factor 4.
*Platelet FXIII-A in Mpl−/− mice is shown as the platelet count (6%) multiplied by the FXIII-A content per platelet (100%).
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in WT and Mpl−/− mice (Figure 3F). This shows that, as in heart 
and aorta, the FXIII-Apos cells in the brain do not arise from 
the platelet lineage. Moreover, FXIII-A mRNA was depleted 
from the brain of the Pf4-cre.Flox mouse (Figure 3F), sug-
gesting that YS-derived macrophages, as BM-derived macro-
phages, coexpress Pf4 and FXIII-A.
Table 2 shows that the Pf4-cre-mediated reduction in car-
diac FXIII-A mRNA (to <1%) greatly exceeds the depletion 
of the plasma FXIII-A (to ≈20%), making it unlikely that the 
majority of cardiac cells contribute to the plasma FXIII-A 
pool. However, in aorta, we observed a similar profile of 
depletion of FXIII-A mRNA (to ≈14%) to plasma FXIII-A. 
We, therefore, conclude that plasma FXIII-A is released 
from cells, similar or identical to those present in the aorta, 
and that these cells resemble YS-derived macrophages.
BMT Repopulates Resident Macrophages 
in Heart and Aorta and Reconstitutes 
Plasma FXIII-A in FXIII-A−/− Mice
BM was transferred from WT mice into irradiated FXIII-A−/− 
and WT recipients; survival was 7 of 8 in both groups. At 10 
weeks post-BMT, FXIII-A−/− recipients expressed normal 
levels of plasma and platelet FXIII-A (Figure 4A). Recipient 
genotype at harvest was confirmed by showing that liver 
gDNA remained predominantly FXIII-A−/−, while a minor 
proportion became FXIII-A+/+, consistent with engraftment of 
donor macrophages (Figure 4B). FXIII-A mRNA expression 
was detectable in hearts, aortas, and brains of the recipient 
FXIII-A−/− mice (Figure 4C), the expression in brain being 
the consequence of irradiation breaching the blood–brain bar-
rier.22,23 There was no increase in plasma FXIII-A or FXIII-A 
mRNA after BMT into WT recipients, suggesting that there 
are a limited number of niches that become occupied by 
FXIII-A-expressing cells.
Discussion
Previously, we demonstrated that plasma FXIII-A levels are 
normal in the thrombocytopenic Mpl−/− and BCl
x
Plt20/Plt20
 mice.3 
However, we did not assay platelet FXIII-A in the Mpl−/− mouse, 
in which depletion of ≈94% platelets and their precursors results 
from knockout of the thrombopoietin receptor.24 Here, we have 
shown that the amount of FXIII-A per platelet has not increased 
to compensate for thrombocytopenia. Platelets arise from frag-
mentation of megakaryocytes25; therefore, cytosolic FXIII-A 
concentrations in megakaryocytes from the Mpl−/− mouse should 
also be unchanged. This makes it improbable for platelets and 
megakaryocytes to be major contributors to the plasma FXIII-A 
pool, although we cannot exclude a minor contribution.
We next compared the effects of recombination by lineage-
specific cre mice on plasma FXIII-A and cellular FXIII-A 
mRNA levels. Plasma FXIII-A, but not platelet FXIII-A, was 
partially depleted in CD11b-cre.Flox and LysM-cre.cre.Flox 
mice, suggesting that macrophages maintain plasma FXIII-A 
and further excluding the megakaryocyte lineage as a major 
contributor.
In Pf4-cre.Flox mice, platelet FXIII-A was abolished, 
while plasma FXIII-A was reduced to 23%. This result 
further supports a macrophage origin for FXIII-A because 
a stop/flox study has established that Pf4-cre expression 
occurs within resident tissue macrophages in addition to 
megakaryocytes.16 Notably, Pf4-cre-mediated recombina-
tion within macrophages is mosaic,16 potentially accounting 
for incomplete depletion of plasma FXIII-A. The FXIII-A-
expressing cells in brain, heart, and aorta have been previ-
ously identified as macrophages,19,20 and consistent with 
this, we show (1) that in heart, as previously demonstrated 
in skin,26 FXIII-A partially co-localizes with the M2 macro-
phage marker CD163 and (2) that in heart, brain, and aorta, 
Pf4-cre depleted FXIII-A mRNA.
CA B
Figure 4. Factor (F)XIII-Apos bone marrow (BM) was transplanted into wild-type (WT) (WT BMT) and FXIII-A−/− (FXIII-A−/− BMT) recipients. 
A, Plasma (red bars) and platelet (blue bars) FXIII-A activity was measured by biotin-pentylamine incorporation assay. Average activi-
ties in nontransplanted mice are shown for comparison. Results are presented as mean±SEM. B, Livers were excised from a single WT 
(lane +) and 3 representative FXIII-A−/− (lanes 1, 2, and 3) recipients of WT BM. Amplification of gDNA by polymerase chain reaction (PCR) 
revealed a preponderance of the deleted allele (200 kDa) in the livers of the FXIII-A−/− recipients and partial repopulation with FXIII-A+/+ 
cells (130 kDa). C, FXIII-A mRNA was measured in the hearts, aortas, and brains of WT (light green bars) and FXIII-A−/− (dark green bars) 
BMT recipients. Results are represented as mean with 95% confidence interval (CI). BMT indicates bone marrow transplant.
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The expression of Pf4-cre within resident macrophages 
is likely to be faithful because expression of Pf4 protein was 
previously demonstrated in adherent cultures of human mono-
cytes27,28 and confirmed by us in mouse BM-derived mac-
rophages. In whole heart, as well as in a FXIII-A-enriched 
cardiac cell fraction, we demonstrated that the ratio of Pf4 
to CD11b transcripts was similar to that in BM-derived 
macrophages, as expected if the Pf4pos cells in the heart are 
macrophages.
The profile of depletion of plasma FXIII-A in the vari-
ous cre/lox crosses (Table 2) closely resembles that of aor-
tic FXIII-A mRNA, implicating cells identical or related to 
aortic resident macrophages as the source of plasma FXIII-A. 
FXIII-A within aortic macrophages has been implicated in 
arterial repair and remodeling.19 If local release contributes to 
this function, this could also suggest that aortic macrophages, 
or cells similar to them, release FXIII-A into the plasma. 
Similarly, placental macrophages express FXIII-A and may 
stabilize this organ during pregnancy.4 Because intravenous 
FXIII-A prevents spontaneous abortion,29 this shows that the 
requirement is extracellular and suggests that placental mac-
rophages can release FXIII-A.
The hypothesis that resident macrophages release plasma 
FXIII-A is consistent with the outcomes of most human BMT 
protocols.9–11 In contrast to Wölpl et al,8 Poon et al11 observed 
that conversion from donor to recipient plasma FXIII-A vari-
ant occurred over many months after BMT. Further, Inbal 
et al9 and Pihusch et al10 observed that BMT caused a much 
greater decrease in platelet count than plasma FXIII-A, which 
led Pihusch et al10 to suggest that resident macrophages main-
tain the plasma pool. Notably, alveolar macrophages persist 
for ≤80 days after BMT.30,31 Further, the results of these stud-
ies seem inconsistent with release occurring from circulating 
monocytes, because, like platelets, these cells are short-lived.32
BMT of FXIII-Apos cells into FXIII-A−/− mice rescued 
plasma FXIII-A to normal levels, while transfer into FXIII-A+/+ 
mice caused no further increase in plasma FXIII-A. This may 
imply that the transplanted cells differentiate within a limited 
number of niches to become FXIII-A-releasing cells.33,34
Recent studies have shown that arterial macrophages arise 
variously from (1) YS macrophages, (2) fetal liver mono-
cytes, and (3) a short wave of BM monocytes.35 To determine 
whether, under normal conditions, monocytes repopulate heart 
and artery and become FXIII-A-releasing cells, we generated 
Fms-like tyrosine kinase 3-cre.Flox mice. These recombine 
in definitive but not primitive hematopoietic cells,36 that is, 
BM and some fetal liver cells37 but not YS-derived cells. The 
Fms-like tyrosine kinase 3-cre transgene becomes fully active 
only in a minority of mice.33,38 One out of 20 Fms-like tyrosine 
kinase 3-cre.Flox mice underwent efficient recombination and 
reduced plasma FXIII-A to 34% (Figure IV in the online-only 
Data Supplement). Assuming that this result is representative, it 
would imply that a proportion of FXIII-A-releasing cells derive 
from fetal liver or BM-derived cells, presumably monocytes. 
This would resemble the situation described for arterial mac-
rophages.35 Our model is shown in Figure 5: the aorto-gonad-
mesonephros is an early site of hematopoiesis,39 and because 
it is known that vascular macrophages in the early embryo 
express FXIII-A,40 it seems probable that they establish here, 
persist within the developing aorta, and survive postnatally. 
Monocyte-derived macrophages subsequently supplement, or 
partially displace, YS-derived macrophages and contribute to 
plasma FXIIII-A. Although we have shown that aortic macro-
phages resemble the plasma FXIII-A-releasing cells, resident 
macrophages in other tissues may contribute.
The main limitation of the present study is that we have 
not directly demonstrated that macrophages release FXIII-A. 
Previously, we detected nonclassical secretion in vitro of 
interleukin-1β, but not FXIII-A, from IL-4-treated adherent 
THP-1 cells, which resemble resident macrophages.41 In addi-
tion, we have detected externalization of the closely related 
protein transglutaminase 2,42,43 but not of FXIII-A, to the sur-
face of mouse macrophages and THP-1 cells (Figure V in the 
online-only Data Supplement). It may transpire that FXIII-A 
is released primarily (1) within tissue niches or (2) from Li6Clo 
resident macrophage precursors,44 and that these cells were 
sparse in culture. Further studies may address these issues by 
(1) adoptive transfer of defined macrophage precursors, (2) 
enriching cultures for particular cell types, or (3) establishing 
coculture models that mimic niches. In conclusion, our studies 
Figure 5. Yolk sac (YS)–derived cells (red) from blood islands 
(pink) colonize the early embryo (gray; 1) and establish in the 
aorto-gonad-mesonephros (AGM; 2). Macrophages migrate from 
the AGM to colonize fetal tissues, including the heart and brain, 
while some establish in the developing aorta (3). Primitive macro-
phages persist postnatally. The onset of hematopoiesis within the 
fetal liver generates monocytes (light blue) that supplement and 
partially displace YS-derived macrophages (4). Both populations 
of resident macrophages can maintain themselves within tissues. 
The onset of hematopoiesis within the BM (white) generates 
monocytes (dark blue), which supplement the aortic and heart 
macrophage population over a short time interval (dotted lines). 
These cells may also differentiate into resident macrophages (5). 
Plasma factor (F)XIII-A is released from cells similar or identical 
to aortic resident macrophages (6), and its origin is distinct from 
platelet FXIII-A (green).
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exclude the platelet and all its precursors as the major source 
of plasma FXIII-A and instead implicate that resident macro-
phages maintain plasma FXIII-A.
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Highlights
• Plasma factor XIII-A derives from resident macrophages.
• Plasma factor XIII-A releasing macrophages resemble aortic macrophages.
• Bone marrow–derived monocytes/macrophages can differentiate in situ into plasma factor XIII-A releasing cells.
